Regenerative cell therapy and pharmacotherapeutic intervention in heart failure Part 2: Pharmacological targets, agents and intervention perspectives

C. Qian, R. G. Schoemaker, W. H. van Gilst*, B. Yu, A. J. M. Roks

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

2 Citations (Scopus)

Abstract

Regenerative medicine represents a promising perspective on therapeutic angiogenesis in patients with cardiovascular disease, including heart failure. However, previous or ongoing clinical trials show ambiguous outcomes with respect to the benefit of regenerative therapy by means of bone marrow stem cell infusion in myocardial infarction patients. Therefore, it is necessary to set up a rational therapeutic strategy in the treatment of congestive heart failure. Chemokines, cytokines and growth factors, as well as pharmaceutical agents, may have an impact on endothelial progenitor cell (EPC) physiology and thus can provide targets for pharmacological intervention. Indeed, EPCs and stein cell niches both in bone marrow and myocardial tissue can be treated as an integral target for recruitment of EPCs from the bone marrow to the cardiac ischaemic niche. In this article, we individually place the signalling factors in their specified context, and explain their roles in the various phases of neovascularisation (see Part 1). (Neth Heart J 2008;16:337-43.)

Original languageEnglish
Pages (from-to)337-343
Number of pages7
JournalNetherlands Heart Journal
Volume16
Issue number10
Publication statusPublished - Oct-2008

Keywords

  • angiogenesis
  • bone marrow derived stem cells
  • endothelial progenitor cells
  • heart failure
  • pharmacotherapy
  • ENDOTHELIAL PROGENITOR CELLS
  • ACUTE MYOCARDIAL-INFARCTION
  • COLONY-STIMULATING FACTOR
  • NITRIC-OXIDE SYNTHASE
  • GROWTH-FACTOR
  • IN-VIVO
  • DOSE-ESCALATION
  • ISCHEMIC LIMBS
  • STEM-CELLS
  • MOBILIZATION

Cite this